Miranda Limón JM

No ORCID on file · 1 paper in corpus

rct 2020

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy ·doi:10.1007/s40259-020-00447-6

BACKGROUND: Sandoz adalimumab SDZ-ADL (GP-2017) is an approved adalimumab biosimilar with similar efficacy and comparable safety and immunogenicity to reference adalimumab (ref-ADL) as confirmed by analytical, pharmacokinetic and confirmato…